Disease · MONDO_0018646
sclerosing cholangitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. sclerosing cholangitis. Diseases, record MONDO_0018646. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018646
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- cholangitis, sclerosing, primary sclerosing cholangitis, sclerosing cholangitis (disease)
- Open Targets
- Highest stage of its drugs
- Phase 3, for 8 of its 48 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs48
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VANCOMYCIN | CHEMBL262777 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| CILOFEXOR | CHEMBL4297613 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 4 | 3 | 3 | Drugs and targets |
| NORUCHOLIC ACID | CHEMBL1254990 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BEZAFIBRATE | CHEMBL264374 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ELAFIBRANOR | CHEMBL3707395 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BIFIDOBACTERIUM SPP. | CHEMBL4297912 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| SIMVASTATIN | CHEMBL1064 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VEDOLIZUMAB | CHEMBL1743087 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| URSODIOL | CHEMBL1551 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ALDAFERMIN | CHEMBL4298055 | Protein | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 48
See all 48 drugsTargets33
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR1H4 | Bile acid receptor | 3 | Bile acid receptor FXR agonist | Phase 3 | https://conductscience.org/library/genes/9971 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| PPARD | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor delta agonist | Phase 3 | https://conductscience.org/library/genes/5467 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 2 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| SLC10A2 | Ileal sodium/bile acid cotransporter | 2 | Ileal bile acid transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6555 | Drugs and targets |
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 1 | Arachidonate 5-lipoxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/240 | Drugs and targets |
| CCR2 | C-C chemokine receptor type 2 | 1 | C-C chemokine receptor type 2 antagonist | Phase 2 | https://conductscience.org/library/genes/729230 | Drugs and targets |
| CCR5 | C-C chemokine receptor type 5 | 1 | C-C chemokine receptor type 5 antagonist | Phase 2 | https://conductscience.org/library/genes/1234 | Drugs and targets |
| CD2 | T-cell surface antigen CD2 | 1 | T-cell surface antigen CD2 inhibitor | Phase 1 | https://conductscience.org/library/genes/914 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 2 | https://conductscience.org/library/genes/51185 | Drugs and targets |
1 to 10 of 33
See all 33 targetsTrials66
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03890120 | Study of Cilofexor in Adults With Primary Sclerosing Cholangitis | Phase 3 | 419 | 2023-11-29 | Primary Sclerosing Cholangitis | CILOFEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT01672853 | Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) | Phase 2 | 235 | 2019-10-22 | Primary Sclerosing Cholangitis (PSC) | SIMTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00059202 | Trial of High-dose Urso in Primary Sclerosing Cholangitis | Phase 2/3 | 150 | 2021-04-08 | Primary Sclerosing Cholangitis | URSODIOL | Its record names the disease | ClinicalTrials.gov |
| NCT04480840 | Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) | Phase 2 | 121 | 2026-01-23 | Primary Sclerosing Cholangitis | BEXOTEGRAST | Its record names the disease | ClinicalTrials.gov |
| NCT02177136 | Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) | Phase 2 | 77 | 2018-05-30 | Primary Sclerosing Cholangitis (PSC) | OBETICHOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02704364 | A Study of NGM282 in Patients With Primary Sclerosing Cholangitis | Phase 2 | 62 | 2025-06-17 | Primary Sclerosing Cholangitis | ALDAFERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT03333928 | A POC and Dose-Ranging Study of HTD1801 in PSC Patients | Phase 2 | 59 | 2022-04-06 | Primary Sclerosing Cholangitis (PSC) | BERBERINE URSODEOXYCHOLATE | Its record names the disease | ClinicalTrials.gov |
| NCT02943460 | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis | Phase 2 | 52 | 2019-03-12 | Primary Sclerosing Cholangitis | CILOFEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT01085760 | A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis | Phase 1 | 35 | 2013-09-19 | Primary Sclerosing Cholangitis | METRONIDAZOLE, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01802073 | Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects | Phase 3 | 34 | 2018-09-21 | Primary Sclerosing Cholangitis | VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsComparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Developed Varices | 15 of 76 | 5 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants With Treatment Failure | 30 of 76 | 19 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Deaths | 5 of 76 | 3 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Meeting Minimal Listing Criteria for Liver Transplantation | 13 of 76 | 10 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Developed Cholangiocarcinoma | 2 of 76 | 2 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Developed Cirrhosis | 6 of 76 | 4 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: deaths from any cause | 5 of 76 | 3 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Have a Liver Transplantation | 11 of 76 | 5 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: serious adverse events | 0 of 76 | 0 of 74 | 150 | NCT00059202 | Trial comparisons |
| Oral Vancomycin-Children vs Oral Vancomycin-Adults: deaths from any cause | 0 of 14 | 0 of 20 | 34 | NCT01802073 | Trial comparisons |
1 to 10 of 18
See all 18 comparisons in its trialsPapers from its trials32
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018646
GET https://conductscience.org/api/diseases/v1/MONDO_0018646/drugs?page=2